Skip navigation
Skip navigation
You are using an outdated browser. Please upgrade your browser.

Platform Computing, the leader in distributed computing software, today announced that Incyte Genomics, the leading genomic information company, has chosen Platform LSF and Platform Analyzer to manage its 1,200 CPU Linux and Unix compute farm. Over the next six months, Incyte will create a dedicated production pipeline to optimise its enterprise compute resources, which should significantly impact time to market and enable Incyte to launch new and revised information products faster than ever before.

“We are extremely pleased with the delivery of Platform LSF from a performance standpoint. Greater computing capability is now available to more personnel at Incyte,” said Stuart Jackson, Director of Bioinformatics for Incyte Genomics. “Our testing ranks the Platform LSF software as a well-built, extremely reliable and top-quality solution in comparison with competing products.”

Prior to putting Platform LSF into production, Incyte used Platform’s performance management tool, Platform Analyzer, to collect baseline utilisation statistics for the cluster, such as system load, CPU usage, pending jobs by user and job pending time. With these results, Incyte was able to make changes to maximise its computing power. Incyte is continuing to use Platform Analyzer to monitor these machines.

“Platform Analyzer provides us with easy-to-understand reports that help us to present actual utilisation figures to both our users and management for use in capacity planning,” continued Incyte’s Jackson. “A sharp increase in the overall utilisation of the environment was also evident to us after Platform LSF was installed and enabled.”

By optimising its resources through Platform LSF, Incyte increased its overall productivity by 50 per cent in the first month after implementation. To date, two million jobs have run through Platform LSF.

“Incyte needed to optimise the computing capacity of its existing Linux clusters to accelerate the discovery and development of new diagnostic and therapeutic products,” said Yury Rozenman, Director, Life sciences Business Development, Platform. “With our performance management solution, Platform Analyzer, Incyte gained visibility into the use of their distributed IT resources to identify fundamentally under-performing IT assets and improve productivity, resulting in faster time to market and higher quality products.”

Platform Analyzer is an integrated part of Platform’s Performance Management solutions, which help organisations can make more strategic IT decisions through valuable insight into system, application and workload performance across the enterprise.

Originally developed as part of Platform LSF®, Platform Analyzer is a web-based operational reporting tool for system performance that reports on workload throughput and software and hardware utilisation, and transparently gathers, tracks and logs valuable system information from more than 100 indices, such as processing power, memory use, and license utilisation, in one easy-to-use, scalable database.

About Platform

Platform is the world’s leading distributed computing software provider, with desktop to Grid solutions that allow organisations to dramatically improve time to market and quality of results, while maximising their I.T. investment. Platform has strategic relationships with industry leaders including Compaq, HP, IBM, SGI, Sun, LION Bioscience and SAS and its open, scalable software solutions are the choice of more than 1,500 result-driven organisations around the world. Platform is a private company with 400 employees in 14 offices in North America, Europe and Asia.

For more information visit

For more information, please contact:

Richard Bennett or Tamsin Keynton
MCC International
Tel: +44 (0)1962 888100
Fax: +44 (0)1962 888125

This press release was distributed by ResponseSource Press Release Wire on behalf of MCC International Ltd in the following categories: Consumer Technology, Personal Finance, Business & Finance, Computing & Telecoms, for more information visit